Clinical Trials
7 trialsNCT05574881 2024-02-26
Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer
Fudan University
Phase 1/2 Unknown
NCT05806671 2023-04-10
Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05800756 2023-04-06
Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer
Yantai Yuhuangding Hospital
Phase 2 Unknown
NCT05515289 2023-03-10
Study of SHR6390 in Renal Insufficiency and Healthy Subjects
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Unknown
NCT03772353 2023-03-07
PLEASURABLE
Fudan University
Phase 1/2 Unknown
NCT05577923 2022-10-13
Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)
Fudan University
Phase 2 Unknown
NCT05512416 2022-08-23
Neoadjuvant Dalpiciclib Plus Letrozole for HR+/HER2- Breast Cancer
The Affiliated Hospital of Qingdao University
Phase 2 Unknown